Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 120,238

Document Document Title
WO/2016/200827A1
A compound, or a pharmaceutically acceptable salt thereof, having a formula I of: (I) wherein Ar is an arylene or heteroarylene; R1 has a structure of: (II) wherein W is an alkanediyl, alkenediyl, a carbonyl, or a combination thereof; X ...  
WO/2016/197944A1
Disclosed are uses of an antidepressant compound in the preparation of antidepressant drugs and antidepressant health foods, wherein the antidepressant compound has the structure of formula I. The antidepressant compound is used as a uni...  
WO/2016/199430A1
Provided is a theranostic bubble preparation which makes it possible to diagnose and treat a tissue of interest by the irradiation with ultrasound such as diagnostic ultrasound and low-intensity therapeutic ultrasound. The theranostic bu...  
WO/2016/197945A1
The present invention relates to the use of a composition for preparing a medicament for the treatment of amyotrophic lateral sclerosis and associated disorders. The composition comprises 3-methyl-1-phenyl-2-pyrazoline-5-one or pharmaceu...  
WO/2016/198627A1
The present invention relates to methods and pharmaceutical compositions for the treatment of Alzheimer's disease. In particular the present invention relates to a method of treating Alzheimer's disease in a subject in need thereof compr...  
WO/2016/198374A1
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...  
WO/2016/198878A1
The present invention relates to interferon-gamma (IFN-γ) inhibitors, and their utility in treating or controlling diseases that can be treated or controlled through inhibition of IFN-γ production, such as Alzheimer's disease, prion di...  
WO/2016/199892A1
The purpose of the present invention is to provide a therapeutic agent that is more effective in refractory amyloidosis. More specifically, it is to provide a novel substance that is highly safe and has a TTR protein amyloid fibril forma...  
WO/2016/198645A1
The invention relates to the use of HNRNPC-expressing vectors for preventing and/or treating a tauopathy, such as Alzheimer's disease. The invention relates to methods for detecting a risk of developing a tauopathy such Alzheimer's disea...  
WO/2016/197987A1
The present invention provides a heterocyclic compound serving as a Syk inhibitor and/or a Syk-HDAC dual inhibitor. Specifically, the present invention provides a compound represented by formula (I), wherein each group is defined by a de...  
WO/2016/198401A1
A series of substituted indazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neuro...  
WO/2016/201168A1
The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, co...  
WO/2016/198663A1
New 2-(pyrazolopyridin-3-yl)pyrimidine derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).  
WO/2016/198398A1
A series of substituted fused tricyclic imidazo pyrazine derivatives and analogues thereof, represented by formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of vari...  
WO/2016/193551A1
Compounds of formula I (formula I), wherein A is an optionally substituted five-membered unsaturated heterocyclic ring containing 1, 2 or 3 N, O or S ring heteroatom(s) exhibit alpha2C antagonistic activity and are thus useful for the tr...  
WO/2016/196328A1
The present invention relates to compositions and methods for promoting the degradation of misfolded proteins and protein aggregates. The compositions and methods may be used to treat a disorder associated with misfolded proteins or prot...  
WO/2016/191935A1
The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). Th...  
WO/2016/191895A1
The invention relates to self-assembled nanofibres of chitosan and bioactive compounds, which can be used as nutraceuticals or drugs. The bioactive compounds suitable for the nanofibres of the invention are molecules of a low molecular s...  
WO/2016/195164A1
The present invention relates to a composition for preventing, ameliorating, or treating neurodegenerative disorders, containing, as active ingredients, turmeric, gastrodia, milkwort, Salvia miltiorrhiza, Chinese quince, white woodland p...  
WO/2016/192657A1
The invention relates to substituted piperazine compounds and methods of use and uses thereof, and further to the pharmaceutical compositions comprising the compounds and uses thereof, wherein the compound has Formula (I) or a stereoisom...  
WO/2016/194638A1
The present invention provides a honey fraction which is obtained by a method comprising (a) a step for obtaining an adsorption component by bringing a honey into contact with an adsorbent, (b) a step for obtaining an organic solvent fra...  
WO/2016/196417A1
The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The presen...  
WO/2016/193234A1
The present invention relates to ethynyl derivatives of formula (I) wherein R1 is hydrogen or F; n is 1 or 2 or to a pharmaceutically acceptable acid addition salt thereof. It has now surprisingly been found that the compounds of general...  
WO/2016/195088A1
Provided is a novel mental illness therapeutic agent. A mental illness therapeutic agent having an IL-6 inhibitor as an active ingredient.  
WO/2016/192687A1
The agents that inhibit system x c - provide the therapeutic intervention in substance-related and addictive disorders and the treatment and/or prevention in substance-mediated brain damage, and confirm that system x c -is a promising th...  
WO/2016/193235A1
The present invention relates to compounds of formula I wherein R1' is CH3; R1 is methyl, ethyl, CF3, cyclopropyl, CH2OH or R1' and R1 may form together with the carbon atom to which they are attached a 1,1- dioxo-thiolan-3-yl ring; R2 i...  
WO/2016/195526A1
The invention relates to veterinary science. A sedative composition with the effect of reducing sexual excitement in dogs and cats contains, in one dose per 10 kg body weight of the animal: 5-100 mg theanine; 2-16 mg tryptophan. The c...  
WO/2016/194131A1
[Problem] The purpose is to provide a ginsenoside composition derived from ginseng that is useful for use in oral compositions and body-related parenteral compositions. [Solution] A ginsenoside composition containing both CK and XVII, wh...  
WO/2016/196071A1
The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). Th...  
WO/2016/191869A1
There is a need for delivery platforms with robust capacity that offer the possibility to deliver diverse protein-based therapeutics into specific cells. Described herein is a platform for delivering cargo polypeptides into cells, which ...  
WO/2016/192667A1
Provided are a thiazolopyrimidinone compound represented by chemical formula (I), preparation method thereof, and use thereof in the preparation of drugs for treating central nervous system diseases, wherein X = O or S, Y = C or N, and w...  
WO/2016/192525A1
The present invention is directed to compounds, pharmaceutical compositions, and related methods of treatment and/or prevention for neurodegenerative diseases, such as Parkinson's disease.  
WO/2016/191855A1
The present invention relates to diene nitrile compounds with anti-convulsant activity and can also be used to treat pain. These compounds are useful in modulating voltage-gated sodium channel activity and can be used in the treatment of...  
WO/2016/196978A1
The present invention provides methods for treating a neurological disease such as ALS in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for treating neuroinflammati...  
WO/2016/194831A1
The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.  
WO/2016/197009A1
The invention relates to triazole compounds of formula I and I' or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising...  
WO/2016/191312A1
The invention provides compounds having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated w...  
WO/2016/189087A1
The present invention relates to a pharmaceutical composition which includes a biocompatible polymer and a eukaryotic cell to be used as a drug for the prevention and/or treatment of tissue lesions of the central nervous system caused by...  
WO/2016/189876A1
The present invention provides a urea derivative or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing t...  
WO/2016/191418A1
The present disclosure relates to nucleic acid promoter sequences that are able to specifically express genes operatively linked to the promoter in brainstem and spinal motor neuron cells, and to methods for using such promoters to selec...  
WO/2016/188816A1
The present invention relates to the compounds of formula I' for use in the treatment of epilepsy, epileptogenesis, seizure disorders and convulsions.  
WO/2016/190780A1
The invention relates to the use of deoxyribonuclease (DNase) enzyme for inhibiting progression and for prevention and treatment of neurodegeneration.  
WO/2016/189393A1
The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retain...  
WO/2016/190766A1
The present invention relates to methods of treating and managing Parkinson's disease and related disorders. The methods especially find use in managing motor symptoms, including gait problems, particularly during advanced stages when ef...  
WO/2016/189877A1
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the...  
WO/2016/190263A1
Provided are: an excellent anti-human NGF antibody fragment that maintains high neutralizing activity and exhibits localized action while reducing systemic side effects from systemic exposure; and a therapeutic procedure for postoperativ...  
WO/2016/189501A1
Abstract of the invention: The present invention is related to a process for the large scale preparation of a nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibitor and also relates to polymorphs of that compound, and to m...  
WO/2016/187722A1
Ocular compositions comprising a CB2 target agent and a cannabimimetic agent that is a non-selective cannabinoid receptor agent are useful in the treatment of ocular inflammation and ocular neuropathic pain. The CB2 target agent may be a...  
WO/2016/190002A1
The present invention addresses the problem of providing a donepezil-containing adhesive patch causing reduced skin irritability. The present invention is an adhesive patch including a support and an adhesive layer positioned on the supp...  
WO/2016/191351A1
Pharmaceutical compositions comprising L-4-chlorokynurenine and associated therapeutic methods are provided for the treatment of certain neurological and other conditions.  

Matches 201 - 250 out of 120,238